This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Prophylaxis versus DVT

Authoring team

There is no current worldwide consensus on which patients should receive thromboprophylaxis. A UK survey suggested that 71% of patients assessed to be at medium or high risk of developing DVT did not receive any form of pharmacological or mechanical Thromboprophylaxis (1).
The following measures could be used to prevent occurrence of DVT:

  • general measures
    • mobilisation and leg exercise - immobility increases the risk of DVT about tenfold, hence in patients recently immobilised, early mobilisation and leg exercises should be encouraged
    • adequate hydration - specially in immobilised patients (2)
    • prophylactic measures prior to elective surgery include:
      • stop oral contraceptives 4 weeks before the operation
      • weight reduction if grossly overweight
      • patients rendered immobile during a period of in-patient investigation benefit from a spell of 2-3 week activity before readmission
      • aspirin prior to admission for surgery reduces the risk of developing DVT
  • mechanical methods - aimed at increasing mean blood flow velocity in leg veins and reducing venous stasis
    • anti-embolic stockings (AES)
    • intermittent pneumatic compression devices (IPCD)
      • these devices periodically compress the calf and/or thigh muscles of the leg stimulating fibrinolysis as well as blood flow
      • usually used immediately before surgery and are often used along with AES during and after surgery (2)
    • foot impulse devices, also known as foot pumps (FID)
  • pharmacological methods
    • the choice of pharmacological agents should be based on local policies and individual patient factors, including clinical condition (such as renal failure) and patient preferences
    • some of the pharmacological agents used are:
      • unfractionated heparin (UFH) and low molecular weight heparins (LMWHs) (usually enoxaparin or dalteparin) (3)
        • given in lower doses than that of treatment of established thromboembolism
        • usually given for at least five days or until discharged from hospital
        • in continued illness and immobility, prolonged prophylaxis may be indicated (2)
      • fondaparinux - a selective factor Xa inhibitor
      • vitamin K antagonists - mainly warfarin, but also acenocoumarol, phenindione, and dicoumarol
      • aspirin
      • newer agents - Dabigatran, Rivaroxaban (1,2,3)

Note:

  • assess all patients for risk of bleeding before offering pharmacological VTE prophylaxis. Do not offer pharmacological VTE prophylaxis to patients with any of the risk factors for bleeding, unless the risk of VTE outweighs the risk of bleeding

Reference:

 


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.